Validation issues frequently seen with initial MAAs
Validation issues frequently seen with initial MAAs. ... GCP Compliance (see also Q.3.4.1 of the Pre-Authorisation guidance) ... • list of GCP inspections conducted/planned by any regulatory authority (indicating the site inspected/to be inspected, the date of inspection and the regulatory authority involved). ...
Download Validation issues frequently seen with initial MAAs
Information
Domain:
Source:
Link to this page:
Documents from same domain
Q12 Step 2b Technical and regulatory …
www.ema.europa.euICH guideline Q12 on technical and regulatory considerations for pharmaceutical product lifecycle management EMA/CHMP/ICH/804273/2017 Page 3/36
Guideline on good pharmacovigilance practices …
www.ema.europa.eu9 December 2013 . EMA/816292/2011 Rev 1* Guideline on good pharmacovigilance practices (GVP) Module VII – Periodic safety update report (Rev 1)
Guideline on good pharmacovigilance practices (GVP)
www.ema.europa.euGuideline on good pharmacovigilance practices (GVP) – Module IX (Rev 1) EMA/827661/2011 Rev 1 Page 2/25
Guideline on good pharmacovigilance practices …
www.ema.europa.euGuideline on good pharmacovigilance practices (GVP) – Module VIII (Rev 3) EMA/813938/2011 Rev 3 Page 2/28
Guideline for good clinical practice E6(R2)
www.ema.europa.euGuideline for good clinical practice E6(R2) EMA/CHMP/ICH/135/1995 Page 2/70 Document History First Codification History Date New Codification
Guideline for good clinical practice E6(R2)
www.ema.europa.euGuideline for good clinical practice E6(R2) EMA/CHMP/ICH/135/1995 Page 2/75 10 Document History 11 First Codification History Date New Codification November
Guideline on good pharmacovigilance practices …
www.ema.europa.euharmful physical or psychological effects [DIR 2001/83/EC Art 1(1 6)]. 74 Adverse event (AE); synonym: Adverse experience 75 Any untoward medical occurrence in a patient or clinical- trial subject administered a medicinal product
European Medicines Agency
www.ema.europa.eu© EMEA 2006 2 SPECIFICATIONS: TEST PROCEDURES AND ACCEPTANCE CRITERIA FOR BIOTECHNOLOGICAL/BIOLOGICAL PRODUCTS ICH Harmonised Tripartite Guideline
products1/traditional herbal medicinal products
www.ema.europa.euThere is no expectation that existing herbal medicinal products on the market will be affected by this guideline, with the exception of traditional herbal medicinal products for human use that were already
Q7 Q&A - good manufacturing practice for active ...
www.ema.europa.euICH guideline Q7 on good manufacturing practice for active pharmaceutical ingredients – questions and answers EMA/CHMP/ICH/468930/2015 Page 2/37
Related documents
The Scope of Regulatory Affairs in the Pharmaceutical Industry
hygeiajournal.comMethod Validations, Process Validations, Master Validation Plan, Protocols, Standard Operating Procedures (SOPs), Auditing and Compliance Functions, Regulatory strategies, Regulatory agencies, legislation and documentation systems as required for USFDA, UKMCA/UKMHRA, MCC, WHO etc.,
Debt Collection Rule - Consumer Financial Protection Bureau
files.consumerfinance.govThis guide meets the requirements of s ection 212 of the Small Business Regulatory Enforcement Fairness Act of 1996 with regard to the Debt Collection Rule and is a Compliance Aid issued by the Consumer Financial Protection Bureau.
Regulatory Reporting Introduction and Overview
www.newyorkfed.orgCompliance. 3 4 Purpose of Regulatory Reports ... practices leading to inaccurate regulatory reports. 35 Data Integrity Issues Data integrity issues Inter-company (related party transactions) ... processes include the validation and enhancement of regulatory reporting data integrity
R: Regulatory Compliance and Validation Issues A …
www.r-project.orgR: Regulatory Compliance and Validation Issues A Guidance Document for the Use of R in Regulated Clinical Trial Environments October 18, 2021 The R Foundation for Statistical Computing c/o Institute for Statistics and Mathematics Wirtschaftsuniversit at Wien Welthandelsplatz 1 1020 Vienna, Austria Tel: (+43 1) 31336 4754 Fax: (+43 1) 31336 904754